Wednesday, April 2, 2025
4/2/2025
Immunopathogenesis in fungal asthma - The objective of this competitive renewal R01 is to continue to uncover mechanisms that contribute to the severity of disease in the 30%+ of asthmatics who are sensitized to fungi. Leukotrienes, immunopathogenic mediators derived from the metabolism of arachidonic acid (AA) by 5-lipoxygenase (5-LOX), are often elevated in severe asthma. As such, this pathway is a therapeutic target of the FDA-approved anti-asthmatic drugs Zileuton®/Zyflo® (inhibits 5-LOX) and Singulair®/Montelukast® (leukotriene receptor antagonist). A second enzyme involved in AA metabolism is 12/15-lipoxygenase (12/15-LOX). We show that asthmatic C57BL/6 wild-type mice have increased lung expression of Alox15 mRNA as well as increased levels of the 12/15-LOX product 12-HETE compared to naïve or vehicle treated mice. Asthmatic 12/15-LOX deficient mice (Alox15-/-) demonstrated lower airway hyperactivity (AHR) in the presence of lower type 1 and type 2-associated mediators, lower chemokine levels and decreases in multiple myeloid cell types. Bone marrow chimera studies identified 12/15-LOX expression in hematopoietic cells as contributing to exacerbation of allergic fungal asthma. Intriguingly, the absence of 12/15-LOX expression in dendritic cells and/or macrophages (via Cd11c Cre/Alox15 floxed mice) had no effect on AHR, implicating other hematopoietic cells in driving 12/15-LOX mediated AHR during allergic fungal asthma. In other data, we demonstrate the development of a 12/15-LOX reporter mouse in which 12/15- LOX is HA-tagged and show feasibility of using these mice to identify 12/15-LOX expressing cells in the lung by flow cytometry. Thus, 12/15-LOXHA mice will serve as a novel tool to identify hematopoietic/myeloid cell type(s) expressing 12/15-LOX during allergic fungal asthma. In other studies, we found that mice deficient in immune response gene 1 (Irg1-/-) (also known as aconitate decarboxylase, Acod1), which generates the immunomodulatory TCA cycle metabolite itaconate, clear A. fumigatus from the lung more efficiently, seemingly as a result of increased proinflammatory responses and augmented macrophage and neutrophil antifungal activity. In contrast, Irg1/Acod1-/- subjected to allergic fungal asthma had increased AHR, indicating a protective role for itaconate. Collectively, we hypothesize that the severity of allergic fungal asthma is dictated by the balance between specific lipidomic (i.e. 12/15-LOX) and metabolomic (itaconate) responses. The specific aims of the proposal are: (1) to define hematopoietic-associated 12/15-lipoxygenase dependent mechanisms promoting AHR during allergic fungal asthma, (2) to define mechanisms of itaconate-mediated regulation of AHR during allergic fungal asthma and (3) to define the therapeutic potential of 12/15-LOX and itaconate on AHR during allergic fungal asthma.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).